Goldman Sachs Group, Inc. (The) Reiterates $36.00 Price Target for Pfizer, Inc. (PFE)
Pfizer, Inc. (NYSE:PFE) has been given a $36.00 price objective by analysts at Goldman Sachs Group, Inc. (The) in a research report issued on Wednesday. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. Goldman Sachs Group, Inc. (The)’s price target suggests a potential upside of 2.68% from the company’s previous close.
A number of other equities research analysts have also recently issued reports on PFE. Cowen and Company set a $43.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Monday, July 10th. BidaskClub cut shares of Pfizer from a “sell” rating to a “strong sell” rating in a report on Thursday, July 13th. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a report on Friday, July 14th. Jefferies Group LLC restated a “hold” rating and set a $35.00 price target (up from $34.00) on shares of Pfizer in a report on Friday, July 14th. Finally, Sanford C. Bernstein set a $39.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Monday, July 17th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $38.35.
Shares of Pfizer (NYSE:PFE) traded up 1.754% during mid-day trading on Wednesday, hitting $35.675. The stock had a trading volume of 4,783,586 shares. The firm’s 50 day moving average price is $35.86 and its 200-day moving average price is $33.92. Pfizer has a one year low of $29.83 and a one year high of $36.78. The company has a market cap of $212.17 billion, a PE ratio of 26.097 and a beta of 1.00.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same period in the prior year, the company earned $0.61 earnings per share. The business’s quarterly revenue was up .9% compared to the same quarter last year. On average, equities research analysts anticipate that Pfizer will post $2.56 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/01/goldman-sachs-group-inc-the-reiterates-36-00-price-target-for-pfizer-inc-pfe.html.
In other news, insider Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $249,900.00. Following the completion of the sale, the insider now owns 132,124 shares of the company’s stock, valued at $4,492,216. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Ian C. Read sold 197,168 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the sale, the chief executive officer now directly owns 580,318 shares of the company’s stock, valued at approximately $19,730,812. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 464,521 shares of company stock valued at $15,813,961. Company insiders own 0.06% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Pfizer by 2.3% during the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after buying an additional 9,239,499 shares in the last quarter. State Street Corp increased its holdings in shares of Pfizer by 3.5% in the fourth quarter. State Street Corp now owns 320,794,199 shares of the biopharmaceutical company’s stock valued at $10,419,393,000 after purchasing an additional 10,838,463 shares in the last quarter. BlackRock Fund Advisors increased its holdings in shares of Pfizer by 1.5% in the first quarter. BlackRock Fund Advisors now owns 92,489,121 shares of the biopharmaceutical company’s stock valued at $2,741,378,000 after purchasing an additional 1,403,646 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Pfizer by 5.0% in the first quarter. Wellington Management Group LLP now owns 82,813,816 shares of the biopharmaceutical company’s stock valued at $2,454,601,000 after purchasing an additional 3,936,078 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Pfizer by 0.7% in the third quarter. Northern Trust Corp now owns 82,281,610 shares of the biopharmaceutical company’s stock valued at $2,786,877,000 after purchasing an additional 592,775 shares in the last quarter. 69.01% of the stock is owned by institutional investors.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.